Novartis AG (NVS) News
Novartis AG (NVS)
Today's Latest Price: $87.85 USD
Updated Jul 1 4:10pm
Add NVS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter NVS News Items
NVS News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NVS News From Around the Web
Below are the latest news stories about Novartis Ag that investors may wish to consider to help them evaluate NVS as an investment opportunity.
Here’s A 100% Equity Portfolio Even Warren Buffett Would Approve OfEquity100 is an all-equity portfolio for investors who want to maximize their exposure to global stocks. The portfolio is constructed using equity Exchange Traded Funds (ETFs) that collectively invest in over 1,500 stocks from the world’s top companies. These include Microsoft, Amazon, Facebook, Walmart, Alibaba, Novartis and more. The Equity100 portfolio implements a Smart Beta… |
NVS Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG and Encourages Investors to Contact the FirmNEW YORK, June 30, 2020 /PRNewswire/ --Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG ("Novartis" or "the Company") (NYSE: NVS). Investors who purchased Novartis securities are encouraged to obtain… |
Advanced Accelerator Applications to Build Targeted Radioligand Therapy Production Facility in IndianapolisSAINT-GENIS-POUILLY, France, June 30, 2020 /PRNewswire/ -- Advanced Accelerator Applications S.A. (AAA), a Novartis company, today announced it has executed a sales and purchase agreement for land on which a 50,000 square foot targeted Radioligand Therapy (RLT) manufacturing plant will be… |
Novartis nabs five product approvals in JapanNovartis (NVS) announces five simultaneous product approvals in Japan by the Ministry of Health, Labor and Welfare:Tabrecta (capmatinib): an oral MET inhibitor for MET exon 14 skipping mutation-positive advanced/recurrent unresectable non-small cell lung cancer.Entresto (sacubitril valsartan sodium hydrate) in chronic heart failure.Mayzent (siponimod fumaric acid) in secondary progressive multiple sclerosis.Enerzair... |
As Greece aims to seek compensation from Novartis, concerns about expired offenses, Stavros Papantoniou, Ioanna Mandrou, Tasos Telloglou | KathimeriniGreece aims to seek financial compensation from Swiss drugmaker Novartis in connection with the bribery scandal concerning which the company settled out of court in the United States, government spokesman Stelios Petsas said on Friday. Meanwhile, Greek judicial officials expressed concern that most of the offenses found to have been committed by doctors have likely expired under the statute of limitations. |
New Agreements to Expand Access to 20 Lifesaving Cancer Medicines for Countries in Sub-Saharan Africa and AsiaATLANTA, June 29, 2020 /PRNewswire/ -- The American Cancer Society (ACS) and the Clinton Health Access Initiative (CHAI) today announced agreements with pharmaceutical companies Pfizer, Novartis, and Mylan to expand access to 20 lifesaving cancer treatments in 26 countries in sub-Saharan… |
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment optionsBasel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW)… |
Novartis Gets Positive CHMP View for Cosentyx Label ExpansionNovartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years. |
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developedInovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity. |
These 6 health-care stocks are ‘buys’ because they can thrive under either Trump or BidenTarget shares of innovative companies whose products and services will gain in popularity no matter what changes are made to the U.S. health-care system. |
